‡ In these countries please contact our distributor


IODOSORB Cadexomer Iodine Ointment

IODOSORB Cadexomer Iodine Ointment


Promote an environment

conducive to healing1

For chronic exudative leg ulcers, IODOSORB ointment is highly absorbent, helping to manage exudate and disinfect wounds2-7

Excessive exudate can lead to prolonged inflammation and tissue maceration,8,9 and slow down or prevent cell proliferation.10

Where infection occurs, the healing process can be stalled11 and potentially lead to a prolonged inflammation cycle11,12 and tissue damage. 11,12

Infected foot ulcers are shown to be 11 times more likely to lead to amputation. 13  

IODOSORB absorbs exudate and acts as a wound disinfectant

IODOSORB helps wound bed preparation and promotes an environment conducive to healing:

-Capable of absorbing 6 times its own weight in wound exudate2,4,5,14 

-Cadexomer beads swell as they absorb exudate, filling cavities and maintaining close contact to the wound -environment2,4,5,14 

-Helps to remove exudate, pus, and debris from the wound2-7 



Helping you get CLOSER TO ZEROdelay in wound healing


  Reg No: 37/14.1/0333. 

Each gram of sterile ointment contains 0,500 g of cadexomer iodine equivalent to 0,491g of cadexomer and 0,009g of iodine. For full prescribing information please refer to the package insert approved by the Medicine's Regulatory Authority.


  1. Drolshagen C, et al. . Poster. in SAWC Anaheim (1999). doi:10.1016/S0140- 6736(02)93145-4;

  2. Skog E, Arnesjo B, Troeng T, et al. A randomized trail comparing cadexomer iodine and standardtreatment in the out-patient management of chronic venous ulcers. British Journal of Dermatology.1983;109:77-83.

  3. Sundberg J, Meller R. Wounds. 1997;9:68-86;

  4. Troeng T, Skog E, Arnesjo B, et al. A Randomised Multicentre Trial to Compare the Efficacy ofCadexomer Iodine and Standard Treatment in the Management of Chronic Venous Ulcers in Out-Patients. Stuttgart: Schattauer Verlag; 1983.

  5. Ormiston MC, Seymour MTJ, Venn GE, Cohen RI, Fox JA. Controlled trial of Iodosorb in chronicvenous ulcers. British Medical Journal. 1985;291:308-310.

  6. Hansson C, Persson L-M, Stenquist B, et al. The effects of cadexomer iodine paste in the treatmentof venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing.International Journal of Dermatology. 1998;37(390-396).

  7. Lindsay G, Latta D, Lyons KGB, Livingstone ED, Thomson W. A Study in General Practise of theEfficacy of Cadexomer Iodine In Venous Leg Ulcers Treated on Alternate Days. Acta Threapeutica.1986;12:141-148.

  8. WUWHS. Principles of best practice: Wound exudate and the role of dressings. A consensusdocument. World (2007);

  9. Trengove NJ, et al. Wound Repair Regen 1996; 4:234–9;

  10. Bucalo B, et al. Wound Repair Regen. 1993; 1:181–186;

  11. Edwards R and Harding KG. Curr Opin. Infect. Dis. 17, 91–96 (2004);

  12. Menke NB, et al. Clin. Dermatol. 25, 19–25 (2007);

  13. Oyibo SO, et al. Diabet Med. 2001;18:133-138;

  14. Smith + Nephew 2017.Review of Perstorp Pharma Absorption Capacity Quality Assurance Data forIODOSORB Ointment/Gel. DS/17/364/R.


How to use IODOSORB ointment 

Step 1: Apply topically to the wound surface to a depth of approximately 3mm. A single application should not exceed 50g, and the total amount used in one week must not exceed 150g. 
Step2: Change approximately three times per week or when the IODOSORB ointment has become saturated with wound exudate, indicated by a loss of colour. 
Step 3: Each time a dressing is changed at the end of treatment, gently remove any remaining IODOSORB from the ulcer surface with a stream of sterile water or saline, or with a sterile moist swab. 

How IODOSORB ointment works

On contact with the wound exudate, cadexomer iodine ointment absorbs fluid, resulting in the formation of a gel over the wound surface.  

The formed gel possesses chromatographic properties and acts as an inverter column. Exudate, pus and debris are removed from the wound surface into the gel matrix.  

In vitro, the absorption of .uid increases the pore size of the carrier base and iodine held within the matrix - in the elemental state - is progressively released against the concentration gradient.   



Known or suspected hypersensitivity to iodine. IODOSORB should not be used by persons who are allergic to iodine. Cadexomer iodine should not be used on patients with Hasimoto's thyroiditis, thyroid disease, patients with a prior history of Grave's disease and non-toxic nodular goitre, or on children or neonates. IODOSORB should not be used during pregnancy or by breastfeeding females.

Drug interactions

There is a potential for interaction of iodine with lithium, sulphafurazoles and sulphonylureas and therefore co-administration is not recommended. IODOSORB ointment should not be used concomitantly with mercurial antiseptics, e.g. Mercurochrome and thiomersal, since there is a risk of metabolic acidosis.

Want more information?

Contact us